Tokuyama T, Yoshinari M, Okamura K, Ikenoue H, Sato K, Kuroda T, Fujishima M
Second Department of Internal Medicine, Faculty of Medicine, Kyushu University.
Nihon Naibunpi Gakkai Zasshi. 1991 Feb 20;67(2):65-74. doi: 10.1507/endocrine1927.67.2_65.
The role of dopaminergic agents (DA) in the regulation of growth hormone (GH) secretion was investigated in patients with untreated acromegaly. TRH (0.5 mg iv), bromocriptine (Br) (2.5 mg orally) or L-Dopa (500 mg orally) loading tests were performed, and serum levels of TSH, GH and prolactin (PRL) were measured. Patients were defined as responders to TRH when peak TSH level after TRH test was higher than 5 microU/ml. Br or L-Dopa was considered to be effective when serum GH or PRL levels were suppressed more than 50% of the basal value. The patients were classified into large adenoma group with suprasellar extension or cisternal herniation (L group, n = 7) and intrasellar small adenoma group (S group, n = 11) which was further divided into TRH responder (Sr group, n = 4) and TRH non-responder with suppressed TSH (Ss group, n = 7). Br was effective in 7 or 100% of 7 patients in the Ss group but only in one or 25% of 4 patients in the Sr group. Br was also effective in 5 or 71% of 7 patients in the L group, although most of them were responders to TRH. Percent inhibition of serum GH levels by Br was significantly higher in the Ss group (82.3 +/- 12.3%, p less than 0.001) and in the L group (64.7 +/- 20.5%, p less than 0.05) compared with that in the Sr group (29.3 +/- 21.6%). Suppression of serum GH level by L-Dopa was also observed in the Ss group. In contrast to the difference in the response of GH, serum PRL level was equally suppressed by Br or L-Dopa in each group. Suppression of TSH by administration of exogenous T4 had no effect on the GH suppression effect of Br in the Sr group. Considering the dual effects of DA to enhance growth hormone-releasing hormone (GHRH) secretion in the hypothalamus and to suppress GH secretion in the pituitary gland, these findings suggest that the paradoxical effect of DA to suppress serum GH level is observed when the hypothalamo-pituitary axis is disturbed mechanically by large adenoma in the L group or functionally in the Ss group probably due to enhanced secretion of somatostatin which suppresses TSH secretion and impairs the effect of GHRH.
在未经治疗的肢端肥大症患者中,研究了多巴胺能药物(DA)在生长激素(GH)分泌调节中的作用。进行了促甲状腺激素释放激素(TRH)(静脉注射0.5毫克)、溴隐亭(Br)(口服2.5毫克)或左旋多巴(口服500毫克)负荷试验,并测量了血清促甲状腺激素(TSH)、GH和催乳素(PRL)水平。当TRH试验后TSH峰值水平高于5微单位/毫升时,患者被定义为对TRH有反应者。当血清GH或PRL水平被抑制超过基础值的50%时,Br或左旋多巴被认为是有效的。患者被分为有鞍上扩展或脑池疝的大腺瘤组(L组,n = 7)和鞍内小腺瘤组(S组,n = 11),后者进一步分为TRH反应者(Sr组,n = 4)和TSH被抑制的TRH无反应者(Ss组,n = 7)。Br对Ss组7例患者中的7例(100%)有效,但对Sr组4例患者中仅1例(25%)有效。Br对L组7例患者中的5例(71%)也有效,尽管他们大多数是TRH反应者。与Sr组(29.3±21.6%)相比,Br对血清GH水平的抑制百分比在Ss组(82.3±12.